[1]方修移,吴小冬,潘美娟,等.罗沙司他治疗慢性肾脏病合并肾性贫血临床价值研究[J].陕西医学杂志,2024,(5):666-670.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.020]
　FANG Xiuyi,WU Xiaodong,PAN Meijuan,et al.Value of roxadustat in the treatment of chronic kidney disease complicated with renal anemia[J].,2024,(5):666-670.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.020]
点击复制

罗沙司他治疗慢性肾脏病合并肾性贫血临床价值研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年5期
页码:
666-670
栏目:
药物与临床
出版日期:
2024-05-05

文章信息/Info

Title:
Value of roxadustat in the treatment of chronic kidney disease complicated with renal anemia
作者:
方修移1; 吴小冬1; 潘美娟1; 江丹丹1; 李 龙2
(1.安徽医科大学附属安庆第一人民医院肾内风湿免疫科,安徽 安庆 246000; 2.贵州医科大学,贵州 贵阳 550004)
Author(s):
FANG Xiuyi; WU Xiaodong; PAN Meijuan; JIANG Dandan; LI Long
(Department of Nephrology and Rheumatology,Anqing First People's Hospital of Anhui Medical University,Anqing 246000,China)
关键词:
慢性肾脏病;  肾性贫血;  罗沙司他;  重组人促红细胞生成素;  铁代谢;  血脂代谢
Keywords:
Chronic kidney disease;  Renal anemia;  Roxadustat;  Recombinant human erythropoietin;  Iron metabolism;  Blood lipid metabolism
分类号:
R 692
DOI:
DOI:10.3969/j.issn.1000-7377.2024.05.020
文献标志码:
A
摘要:
目的:探讨罗沙司他治疗慢性肾脏病(CKD)合并肾性贫血的临床价值。方法:选取慢性肾脏病合并肾性贫血患者102例,根据治疗方法不同分为观察组(45例)和对照组(57例)。对照组给予重组人促红细胞生成素(rHuEPO)治疗,观察组给予罗沙司他治疗,共治疗12周。比较两组患者疗效、贫血相关指标[血红蛋白(Hb)、血细胞压积(HCT)、红细胞计数(RBC)]、铁代谢指标(铁蛋白、血清铁、总铁结合力)、血脂代谢指标[胆固醇(CHOL)、甘油三酯(TG)、低密度脂蛋白(LDL)]及不良反应发生情况。结果:治疗第12周时,观察组总有效率高于对照组(P<0.05)。治疗第8、12周时,观察组铁蛋白水平低于对照组,血清铁及总铁结合力水平高于对照组(均P<0.05)。治疗第8、12周时,观察组Hb高于对照组,TG及LDL水平低于对照组(均P<0.05)。治疗第12周时,观察组RBC、HCT高于对照组,CHOL低于对照组(均P<0.05)。治疗12周内,两组患者不良反应总发生率比较差异无统计学意义(P<0.05)。结论:对于CKD合并肾性贫血患者,罗沙司他治疗效果较rHuEPO好,能更好地改善贫血相关指标,调节铁代谢及血脂代谢,且安全性较好。
Abstract:
Objective:To investigate the clinical value of roxastat in the treatment of chronic kidney disease(CKD)complicated with renal anemia.Methods: A total of 102 patients with chronic kidney disease complicated with renal anemia were divided into observation group(45 cases)and control group(57 cases)according to different treatment methods.The control group was treated with recombinant human erythropoietin(rHuEPO)and the observation group was treated with roxadustat for 12 weeks.The efficacy,anema-related indexes(hemoglobin [Hb],hematocrit [HCT],red blood cell count [RBC]),iron metabolism indexes(ferritin,serum iron,total iron binding capacity),lipid metabolism indexes(cholesterol [CHOL],triglyceride [TG],low-density lipoprotein [LDL])and the occurrence of adverse reactions were compared between the two groups.Results: At the 12th week of treatment,the total effective rate of observation group was higher than that of control group(P<0.05).At the 8th and 12th week of treatment,the ferritin levels of observation group were lower than those in of control group,and the serum iron and total iron binding capacity levels were higher than those of control group(all P<0.05).At the 8th and 12th week of treatment,Hb levels in observation group were higher than those in control group,and TG and LDL levels were lower than those in control group(all P<0.05).At the 12th week of treatment,RBC and HCT of observation group were higher than control group,and CHOL was lower than control group(all P<0.05).Within 12 weeks of treatment,there was no significant difference in the total incidence of adverse reactions between the two groups(P<0.05).Conclusion:For patients with CKD complicated with renal anemia,roxadustat has better therapeutic effect than rHuEPO,can better improve anemia related indicators,regulate iron metabolism and lipid metabolism,and has good safety.

参考文献/References:

[1] 杨雄,高伟,邱万胜,等.白蛋白球蛋白比值对慢性肾脏病患者预后判断的价值研究[J].陕西医学杂志,2020,49(6):728-731.
[2] MA A K,AM T,NEA K,et al.Evaluation of iron metabolism in chronic kidney disease patients by serum hepcidin level[J].Benha Journal of Applied Sciences,2022,7(3):159-165.
[3] 张丽君,王蓉,章峰.左卡尼汀注射液对维持性血液透析患者微炎症状态、营养不良及氧化应激的影响[J].陕西医学杂志,2022,51(8):1004-1007.
[4] ISLAM K M,AJMERY S,HUDA M,et al.Prevalence of anemia in chronic kidney disease[J].Medicine Today,2021,33(1):54-57.
[5] 洪义芬,王自强,彭红伟,等.罗沙司他对比促红细胞生成素治疗老年血液透析合并肾性贫血的疗效及对心血管指标的影响[J].中国老年学杂志,2023,43(12):2903-2906.
[6] DEL-VECCHIO L,LOCATELLI F.Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors(HIF-PHI)for the treatment of anemia associated with chronic kidney disease[J].Expert Opin Investig Drugs,2018,27(7):613-621.
[7] 洪大情,田恩,李明珠,等.罗沙司他对慢性肾脏病透析合并肾性贫血患者铁代谢的影响[J].中国实用内科杂志,2020,40(12):1024-1027.
[8] NKF-K/DOQI工作组.慢性肾脏疾病及透析的临床实践指南Ⅱ[M].北京:人民卫生出版社,2013:1-7.
[9] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018 修订版)[J].中华肾脏病杂志,2018,34(11):860-866.
[10] 田晶晶,张圣雨,刘智,等.罗沙司他治疗慢性肾脏病合并肾性贫血的临床观察[J].中国药房,2021,32(22):2772-2777.
[11] 周林,禹红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,44(10):1400-1403.
[12] 喻倩,路香雪,张嘉铃,等.肾性贫血的药物治疗现状与进展[J].中国血液净化,2020,19(9):589-591,597.
[13] 周雅萍,李凯.治疗肾性贫血新药罗沙司他[J].药物评价研究,2018,41(9):1743-1748.
[14] 郭罡玲,武玲宇,樊佩琦,等.罗沙司他治疗红细胞生成素反应低下的血液透析患者肾性贫血的临床研究[J].中国血液净化,2022,21(12):896-900.
[15] 钟小桂.重组人促红素注射液与罗沙司他胶囊治疗维持性血液透析肾性贫血的效果及对血清Hb、SF、CRP的影响[J].吉林医学,2022,43(8):2153-2154.
[16] 孔祥栋,许金华,余杨洁,等.罗沙司他在维持性血液透析患者肾性贫血治疗中的应用效果观察[J].中国医药导报,2020,17(33):126-128.
[17] 王文静,赵艳龙,曾晓荣,等.维持性血液透析患者微炎症状态中医诊疗进展[J].陕西中医,2023,44(4):541-544.
[18] SHU S,WANG Y,ZHENG M,et al.Hypoxia and hypoxia-inducible factors in kidney injury and repair[J].Cells,2019,8(3):207.
[19] 金毅,杨立川.肾性贫血患者血清铁蛋白、TSAT、Cys C及维生素B12水平变化及临床意义[J].川北医学院学报,2022,37(8):1067-1069,1085.
[20] PROVENZANO R,SHUTOV E,EREMEEVA L,et al.Roxadustat for anemia in patients with end-stage renal disease incident to dialysis[J].Nephrology Dialysis Transplantation,2021,36(9):1717-1730.
[21] PROVENZANO R,TUMLIN J,ZABANEH R,et al.Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat(FG-4592)for treatment of anemia in chronic kidney disease:A placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients[J].The Journal of Clinical Pharmacology,2020,60(11):1432-1440.
[22] LU C L,ZHENG C M,LU K C,et al.Indoxyl-sulfate-induced redox imbalance in chronic kidney disease[J].Antioxidants(Basel),2021,10(6):936.
[23] 车家慧,姜鑫鑫,尤菲,等.罗沙司他治疗对糖尿病肾病血液透析合并肾性贫血患者铁代谢相关指标的影响[J].河北医药,2023,45(5):761-765,770.
[24] KAPLAN J M,SHARMA N,DIKDAN S.Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease[J].International Journal of Molecular Sciences,2018,19(2):389.
[25] 郑光毅,洪大情,李贵森,等.罗沙司他对不同铁代谢状态维持性血液透析患者贫血的影响[J].肾脏病与透析肾移植杂志,2021,30(6):536-540.
[26] 陈小妹,陈孜瑾,马晓波,等.维持性血液透析患者左心室肥厚进展情况和相关危险因素分析[J].上海交通大学学报(医学版),2018,38(5):505-509.
[27] 胡菂菂,李恩就,刘娜,等.罗沙司他对维持性血液透析患者肾性贫血的疗效及铁、脂代谢的影响[J].中国医学创新,2023,20(14):50-55.

相似文献/References:

[1]杨 雄,高 伟,邱万胜,等.白蛋白球蛋白比值对慢性肾脏病患者预后判断的价值研究[J].陕西医学杂志,2020,49(6):728.[doi:DOI:10.3969/j.issn.10007377.2020.06.022]
[2]王 萍,王文娟,杜 翔.慢性肾脏病患者肾素-血管紧张素系统与血浆β-淀粉样蛋白相关性研究[J].陕西医学杂志,2022,51(5):574.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.014]
　WANG Ping,WANG Wenjuan,DU Xiang.Correlation between renin-angiotensin system and plasma beta-amyloid peptide in patients with chronic kidney disease and its significance[J].,2022,51(5):574.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.014]
[3]任 翔,过轶斌,张立元.罗沙司他对重组人促红细胞生成素疗效不佳血液透析肾性贫血患者血生化、铁代谢和钙磷代谢的影响[J].陕西医学杂志,2023,52(7):902.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.029]
　REN Xiang,GUO Yibin,ZHANG Liyuan.Effect of roxadustat on blood biochemistry,iron metabolism and calcium-phosphorus metabolism in patients undergoing hemodialysis for renal anemia inadequately controlled by rHuEPO[J].,2023,52(5):902.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.029]
[4]李梦梦,张淑英,赵艳杰.视黄醇结合蛋白、胱抑素C、胃泌素前体释放肽水平联合超微血流成像在慢性肾脏病诊断中的价值研究[J].陕西医学杂志,2024,(4):483.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.010]
　LI Mengmeng,ZHANG Shuying,ZHAO Yanjie.Diagnostic value of RBP,CysC and proGRP in combination with superb micro-vascular imaging in chronic kidney disease[J].,2024,(5):483.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.010]

备注/Memo

备注/Memo:
基金项目:贵州省卫生健康委员会科学技术基金资助项目(GZWKJ2021-141)
更新日期/Last Update: 2024-05-06